LitAlert ~~ GeneLit.com

    • BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance.
    • Scott R, Rimel BJ.
    • OncLive. 2022 Nov 4.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Nov 4.

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Nov 4.

    • Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
    • Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA.
    • JCO Precis Oncol. 2022 Nov;6:e2200309. doi: 10.1200/PO.22.00309.
    • Case report

    • Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.
    • Gross M, Spencer RJ.
    • Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715.